3. “Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic pain, a condition currently without consistently effective therapies. Cara’s most advanced CB compound, CR701, is in preclinical development.”
http://www.caratherapeutics.com/cb-agonists.shtml
Follow Cara Therapeutics Inc. (NASDAQ:CARA)
Follow Cara Therapeutics Inc. (NASDAQ:CARA)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.